Every breath is a right.
Personal site and notebook of Amit Kumar. Twenty-six years in Indian respiratory medicine, ten of them at Cipla and sixteen building Bayu Healthcare.
Currently writing about why India loses so many people to diseases we already know how to control, and building #RTI, the Right to Inhalation: Saans Ka Adhikaar.
Start here
The breath India keeps losingTwenty-six years inside the inhalation therapy market: why the deepest pockets keep failing, and the patient who pays for what we won't say.Essays
Asthma in India
Why a controllable disease kills so many Indians, and where the gap opens.
Medicines we misuse
Relievers sold as treatment, tablets sold as controllers, and the inhaler left on the shelf.
The business of respiratory care
What twenty-six years inside Indian pharma taught me about why this market keeps failing patients.
When doctors are attacked
A three-part series on violence against India's doctors, and who really pays for it.
18 essays, written for doctors, pharma leaders, policymakers and anyone who has watched a family member struggle to breathe.
Get the monthly email
One email a month with new essays and field reports from Indian healthcare. No spam; unsubscribe any time.
Prefer a feed reader? RSS
About
I'm Amit Kumar, co-founder and director of Bayu Healthcare, a respiratory-focused pharmaceutical company based in Lucknow and working across Uttar Pradesh, Bihar, Jharkhand and Madhya Pradesh. Before Bayu I spent a formative decade at Cipla, helping build its respiratory division.
This site is about a question I can't stop asking. In a country where tens of millions of people live with asthma, COPD and allergic airway disease, why is inhalation therapy still treated as a last resort instead of a first-line right? #RTI, the Right to Inhalation, is my attempt at an answer, built in conversation with chest physicians, paediatricians, ENT specialists and the field teams who meet patients every day.
I write about the parts of this business I have spent a career inside, including the parts the industry would prefer stayed in the drawer. I name dysfunctions, not individuals, and I lean on evidence wherever it exists. If you think I'm wrong, or you have a field story I can't see from where I stand, write to me on LinkedIn.
MBA, P.I.M.R. Indore · Executive education, IIM Ahmedabad